Clinical Significance of the Cytochrome P450 2C19 Genetic Polymorphism

By Z. Desta, Xiaojiong Zhao, Jae-Gook Shin, D. Flockhart. Clinical Pharmacokinetics, 2002

966 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/5e8c804ba5d5242066dde2e7e7a4ff612d9c9593

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

In Pharmacology

Citations in the corpus

A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants (2006, background): “The oor metabolizer (PM) phenotype of CYP2C19 affects p to 5% of white subjects and black subjects and pproximately 20% of Asians.(3) Two defective YP2C19 alleles, CYP2C19*2 and CYP2C19*3, cause he majority of PM phenotypes.”
Polymorphism of human cytochrome P450 enzymes and its clinical impact (2009, background): “Indigenous populations, such as the Canadian Indians and the Australian Aboriginals, have a high frequency of PMs, which is similar to that of the Asian population (Desta et al., 2002b).”
Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. (2013, background): “The clinical significance of CYP2C19 has been extensively documented (Goldstein, 2001; Desta et al., 2002; Furuta et al., 2007; Rosemary & Adithan, 2007; Lee, 2013).”
Pharmacogenomics and individualized drug therapy. (2006, background): “8%, in Caucasian Europeans, but as high as 23% in Oriental populations (33, 34).”
Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. (2007, background): “The CYP3A7⁎2 SNP has an allele frequency of 8%, 28% and 62% in Caucasians, Asians and Africans, respectively, and encodes an enzyme with a moderately higher activity than CYP3A7.”
Reduced-Function CYP2C19 Genotype and Risk of Adverse Clinical Outcomes Among Patients Treated With Clopidogrel Predominantly for PCI: A Meta-Analysis (2010, neutral): “The proportion of the population harboring 2 reduced-function CYP2C19 alleles is approximately 2% for whites, 4% for blacks, and 14% for Chinese individuals.(8) The FDA referenced a crossover study of 40 healthy participants who”